Send this to a friend

Biostage running short on cash with IND looming

Biostage, which develops bioengineered organ implants, reported it lost $3.8 million in the first quarter, leaving it with only enough cash through the end of the year, as expenses increased during the company’s transition into its clinical stage.
The Holliston company, which plans to file an investigational new drug (IND) application for its esophageal organ implant with the U.S. Food and Drug Administration in its third quarter ...

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

ADVERTISEMENTS
Copyright 2017 New England Business Media